MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-30-2025
Abbott Laboratories Revenue 2011-2026 | ABT
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Abbott Laboratories
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 42 B | 40.1 B | 43.7 B | 43.1 B | 34.6 B | 31.9 B | 30.6 B | 27.4 B | 20.9 B | 20.4 B | 20.2 B | 21.8 B | 39.9 B | 38.9 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 43.7 B | 20.2 B | 32.5 B |
Quarterly Revenue Abbott Laboratories
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.1 B | 10.4 B | 10.6 B | 10.4 B | 9.96 B | 10.1 B | 9.98 B | 9.75 B | - | 10.4 B | 11.3 B | 11.9 B | - | 10.9 B | 10.2 B | 10.5 B | - | 8.85 B | 7.33 B | 7.73 B | 8.31 B | 8.08 B | 7.98 B | 7.54 B | 7.76 B | 7.66 B | 7.77 B | 7.39 B | 7.59 B | 6.83 B | 6.64 B | 6.34 B | 5.33 B | 5.3 B | 5.33 B | 4.88 B | 5.19 B | 5.15 B | 5.17 B | 4.9 B | 5.36 B | 5.08 B | 5.06 B | 4.76 B | 5.07 B | 4.8 B | 4.93 B | 4.85 B | 5.63 B | 5.26 B | 5.31 B | 5.28 B | 10.4 B | 9.82 B | 9.62 B | 9.04 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 11.9 B | 4.76 B | 7.6 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M |  USA |
 |
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | USA |
 |
AxoGen
AXGN
|
187 M | $ 31.35 | -0.63 % | $ 1.39 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | USA |
 |
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | USA |
 |
Abiomed
ABMD
|
848 M | - | - | $ 17.2 B | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
443 M | $ 9.71 | -0.21 % | $ 697 M |  Israel |
 |
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | USA |
 |
Apyx Medical Corporation
APYX
|
52.3 M | $ 4.06 | 1.2 % | $ 141 M | USA |
 |
Alphatec Holdings
ATEC
|
612 M | $ 17.1 | -2.79 % | $ 2.44 B | USA |
 |
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | USA |
 |
CONMED Corporation
CNMD
|
1.31 B | $ 43.26 | -0.46 % | $ 1.33 B | USA |
 |
Bio-Rad Laboratories
BIO
|
2.57 B | $ 327.18 | 1.28 % | $ 9.23 B | USA |
 |
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | USA |
 |
EDAP TMS S.A.
EDAP
|
44.1 M | $ 4.0 | -2.44 % | $ 149 M |  France |
 |
Bruker Corporation
BRKR
|
3.37 B | $ 51.83 | -2.96 % | $ 7.72 K | USA |
 |
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
16.7 B | $ 94.11 | -1.68 % | $ 138 B | USA |
 |
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | USA |
 |
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Integra LifeSciences Holdings Corporation
IART
|
1.61 B | $ 12.91 | -1.79 % | $ 994 M | USA |
 |
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M |  Canada |
 |
IRIDEX Corporation
IRIX
|
51.9 M | $ 1.34 | -9.41 % | $ 21.6 M | USA |
 |
Zynex
ZYXI
|
192 M | - | - | $ 21.1 M | USA |
 |
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | USA |
 |
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | USA |
 |
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | USA |
 |
Electromed
ELMD
|
64 M | $ 28.4 | -0.73 % | $ 240 M | USA |
 |
Pulmonx Corporation
LUNG
|
83.8 M | $ 1.96 | -1.51 % | $ 76.7 M | USA |
 |
InMode Ltd.
INMD
|
358 M | $ 14.29 | -1.41 % | $ 1.13 B | Israel |
 |
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | USA |
 |
Align Technology
ALGN
|
4 B | $ 172.27 | 0.16 % | $ 12.9 B | USA |
 |
Accuray Incorporated
ARAY
|
459 M | $ 0.86 | -1.0 % | $ 88.4 M | USA |
 |
IRadimed Corporation
IRMD
|
73.2 M | $ 98.4 | 0.51 % | $ 1.25 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
205 M | $ 19.84 | -1.32 % | $ 458 M | USA |
 |
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
31.4 M | $ 14.96 | -4.41 % | $ 404 M | USA |
 |
FONAR Corporation
FONR
|
97.6 M | $ 18.57 | -0.11 % | $ 122 M | USA |
 |
Myomo
MYO
|
1 B | $ 1.0 | 1.02 % | $ 7.05 M | USA |
 |
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | USA |
 |
Orthofix Medical
OFIX
|
799 M | $ 15.28 | 0.2 % | $ 583 M |  Curacao |